Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback on June 01, 2026 Agios Autoimmune thrombocytopenia Cevidoplenib Failure (biologic function) Hematological Disease Inhibitor Inosine Triphosphate ITP Oscotec Phase 2 Clinical Trials SYK +
Miltenyi Bio's CAR-T Clears Triple Autoimmune Burden in Single Patient on April 13, 2026 APLAS Autoimmune Diseases Autoimmune hemolytic anemia CAR-T therapy Disease remission Inosine Triphosphate Miltenyi Biopharma zorpocabtagene-autoleucel ( +
Novartis antibody ianalumab helps prolong control of rare blood disorder ITP on December 10, 2025 Antibodies Asymmetric Septal Hypertrophy Autoimmune thrombocytopenia disorder control (procedure) ianalumab Inosine Triphosphate Novartis rare blood disorder treatment failure VAYHIT2 trial +
Sanofi’s Wayrilz Receives FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia on September 02, 2025 Approved Autoimmune thrombocytopenia BTK inhibitor Inosine Triphosphate LUNA 3 trial Rilzabrutinib sanofi United States Food and Drug Administration Wayrilz +
Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP) on August 12, 2025 Autoimmune Autoimmune thrombocytopenia ianalumab Infrequent Inosine Triphosphate Novartis Phase 3 platelet levels treatment failure VAY736 +